G7‐αPD‐L1 was designed to bind specifically to PD‐L1 on tumor cells after systemic administration, leading to the blockade of PD‐L1 and improved T cells activity.[158] In vitro binding kinetics assays exhibited that G7‐αPD‐L1 possessed enhanced binding avidity to PD‐L1 protein compared to free αPD‐L1. Here, CD274 is linked to neoplasm.